Top Markets
#1 Purr Purr +63.76%
#2 Pons Pons +51.76%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +34.60%
#5 ApeX ApeX +29.89%
#6 Kinetiq Kinetiq +27.29%
#7 Morpho Morpho +24.45%
#8 StonkBroker StonkBroker +23.94%
#9 Cash Cat Cash Cat +23.07%
#10 OriginTrail OriginTrail +21.94%
Coin of the day
Purr Purr
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classifica tra le azioni #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Prezzo delle azioni
$1.54
Ultima sincronizzazione: 2024-04-08
Capitalizzazione di mercato
$119.21M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia NGM Biopharmaceuticals, Inc. (NGM)

Categoria

Healthcare
Il prezzo NGM con la capitalizzazione del mercato della B
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
NGM
$1.54
Capitalizzazione di mercato di NGM Biopharmaceuticals, Inc.(NGM)
Capitalizzazione di mercato: $119.21M
A partire dal August 2026, NGM Biopharmaceuticals, Inc. ha una capitalizzazione di mercato pari a $119.21M. Questo rende NGM Biopharmaceuticals, Inc. la 20909th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di NGM Biopharmaceuticals, Inc. dal 2019 al 2026
NGM in paragone con la classifica dei più popolari stocks
Il prezzo per NGM Attivo B Capitalizzazione del mercato a B Risultati
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$67,322.89 $119.21M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +4,371,516.28%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$58,736.98 $119.21M
Apple Inc. Apple Inc.
AAPL
$4.547T +3,813,989.78%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$53,772.80 $119.21M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +3,491,640.48%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$46,413.34 $119.21M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,013,753.51%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$36,079.39 $119.21M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,342,717.73%